CSO
MD Southwestern Medical School,
MS Chem, Univ of Texas,
MS Physiological Chem,
University of Wisconsin
CSO
Kamlendra Singh is an Associate Professor at the University of Missouri. His team uses computer-aided drug design to examine the molecular interactions between chemical entities and target proteins for designing novel therapeutics for infectious and inflammatory diseases.
CDO
Sriram is an established pharmaceutical R&D professional with 25 years of research experience in multiple therapeutic area, both Drug Discovery R & D and CRO services. Previously, Sriram was CSO for Jubilant Biosys, GVKBio and Bioneeds.
CMO
Parul is a Physician-Scientist with extensive experience in drug discovery, clinical development, and clinical practice. She worked at Synaptic Pharmaceuticals (Lundbeck) and Hackensack Meridian Medical Center.
JD Cornell University BS
Aerospace Engineering Univ. of Texas
MS, MBA
Pat is a seasoned C-level executive with extensive experience in corporate management and entrepreneurship.
MD Kasturba Medical College,
Manipal, India
MBA. Univ. of Colorado, Texas
DO Philadelphia College of Osteopathy, FIDSA, BS University of Richmond
MBBCH(WITS), FCS(SA),
MMed(Surg), Specialist Trauma / Critical
(CMSA)
PhD, MBA (Formulation)
Dr. Hemant Joshi is a pharmaceutical scientist specialized in formulation, pre-formulation, process development and packaging. He is also an expert in developing analytical methods.
PhD (Clinical Development & Regulatory)
Subbu is an established scientist with extensive experience in drug discovery, development and regulatory submissions.
Previously, Subbu was a Drug Discovery & Development Leader at Roche Pharmaceuticals.
PhD (Chemistry)
Dr. Kalicharan Sharma is an expert in Synthetic Organic Chemistry and Molecular Modelling Studies. His specialty includes Molecular modelling studies to find out suitable drug candidate for coronavirus.
Riin Ehin’s academic journey is proof of her unwavering intellectual curiosity and dedication. Her pursuit of knowledge has taken her across diverse fields, including medicine, biology, mathematics, and life sciences, at the esteemed University of Helsinki in Finland and the University of Tartu in Estonia. In addition to her passion for learning, she has also pursued business management and administration studies at the Copenhagen Business School and gained experience in European Structural Fund management across Italy, Belgium, Denmark, and Sweden.
Dr. Hiroshi Ohrui’s academic journey is a testament to his growth and development. He received his Ph.D. degree (1971) from the University of Tokyo under the direction of Professor Masanao Matsui. He then joined RIKEN 1966 as a researcher, beginning his professional career. His journey continued as he moved to Tohoku University in 1981 as an Associate Professor in the Department of Food Chemistry, Faculty of Agriculture. His growth was evident when he was promoted to full professor at the Graduate School of Life Science in 1977. In 2006, he furthered his journey by moving to Yokohama University of Pharmacy as a Professor, a position he held until his recent retirement. Throughout his career, Dr. Ohrui has made significant contributions to his field, which have been recognized with numerous awards and accolades.
Dr. Ohrui’s career is a testament to his significant contributions to the field. His postdoctoral fellowships at the Sloan Kettering Institute for Cancer Research (1972-1973) and Syntex Research (1973-1974) were just the beginning. He furthered his impact at the Technical University of Darmstadt, where he served as an invited professor by DAAD (1990). His contributions have been recognized with several awards, including The Agricultural Society of Japan Award for Young Scientists (1974), Inoue Prize for Science (2001), Japan Prize of Agricultural Sciences (2004), The Japan Society for Analytical Chemistry Award (2004), and The Japan Academy Prize (2010). After a distinguished career, Dr. Ohrui recently retired from the Department of Pharmacy at Yokohama University of Pharmacy, leaving behind a legacy of excellence and innovation.
BS,MS,Ph.D.(Tohuku University)
Dr. Eiichi Ami, holding a BS, MS, and Ph.D. from Tohoku University, completed his Ph.D. in 2000 under the guidance of Prof. Hiroshi Ohrui, a prominent figure in developing the HIV drug Islatravir. His doctoral research focused on designing fluorescent analytical reagents for in vivo detection of trace carboxylic acids and developing nucleoside analogues as anti-HIV drugs. Subsequently, he conducted research in Prof. Craig M. Crews’ laboratory at Yale University. After more than a decade in a leading Japanese pharmaceutical company, he transitioned back to academia during the COVID-19 pandemic. Dr. Ami then held a postdoctoral position in the laboratory of Prof. Arun K. Ghosh at Purdue University, renowned for the discovery of Darunavir. Since 2024, his research has been primarily dedicated to Drug Discovery for Viral Infections in collaboration with Prof. Kamal Singh at the University of Missouri for Adnexus Biotechnologies Inc.
